One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/s0090-8258(22)01241-0
Copy DOI
Export
Save
Share
Cite Journal: Gynecologic Oncology |  Publication Date: Aug 1, 2022 |
 Citations: 1 |
Affiliation: The US Oncology Network, Institute Curie, Pontificia Universidad Católica Argentina, Saitama Medical University, Sheba Medical Center, Istanbul Medeniyet University, Instituto Nacional de Enfermedades Neoplásicas, Centre Hospitalier de l’Université de Montréal, Centre Hospitalier Universitaire de Québec, Université Laval, Ministry of Health of the Russian Federation, Gwynedd Mercy University, University of Milan
Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
